Abstract | BACKGROUND: MATERIALS AND METHODS: RESULTS: Most of the adenocarcinomas (92.5%) bound aviscumine. Kaplan-Meier analysis revealed no correlation between aviscumine binding and progression-free survival or overall survival. CONCLUSION: These results suggest that for the selected group of patients with adenocarcinoma of the lung aviscumine binding activity can not serve as a prognostic factor. More strikingly, however, aviscumine binds to malignant cells in 92.5% of the patients. This is an indicator for the use of aviscumine as a possible target for tumour therapy.
|
Authors | Katharina Blonski, Udo Schumacher, Iris Burkholder, Lutz Edler, Haleh Nikbakht, Ina Boeters, Anja Peters, Christian Kugler, Hans-Peter Horny, Martin Langer, Karin Wilhelm-Ogunbiyi, Klaus Witthohn, Eckart Laack |
Journal | Anticancer research
(Anticancer Res)
2005 Sep-Oct
Vol. 25
Issue 5
Pg. 3303-7
ISSN: 0250-7005 [Print] Greece |
PMID | 16101142
(Publication Type: Journal Article)
|
Chemical References |
- Plant Preparations
- Plant Proteins
- Recombinant Proteins
- Ribosome Inactivating Proteins, Type 2
- Toxins, Biological
- ribosome inactivating protein, Viscum
|
Topics |
- Adenocarcinoma
(metabolism, pathology, surgery)
- Adult
- Aged
- Aged, 80 and over
- Disease-Free Survival
- Female
- Glycosylation
- Histocytochemistry
- Humans
- Lung Neoplasms
(metabolism, pathology, surgery)
- Male
- Middle Aged
- Neoplasm Staging
- Plant Preparations
(metabolism)
- Plant Proteins
(metabolism)
- Recombinant Proteins
(metabolism)
- Ribosome Inactivating Proteins, Type 2
- Toxins, Biological
(metabolism)
|